• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Fresenius Medical Care AG (Amendment)

    2/13/24 1:36:58 PM ET
    $FMS
    Misc Health and Biotechnology Services
    Health Care
    Get the next $FMS alert in real time by email
    SC 13G/A 1 d772544dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (AMENDMENT NO. 1 )*

     

     

    FRESENIUS MEDICAL CARE AG

    (Name of Issuer)

    Ordinary Shares and American Depositary Shares

    (Title of Class of Securities)

    358029106

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    PAGE 1 OF 5 PAGES


    CUSIP NO. 358029106    13G    PAGE 2 OF 5 PAGES

     

     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Dodge & Cox    94-1441976

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     N/A

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     California - U.S.A.

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     18,562,650 Ordinary Shares and 4,223,110 American Depositary Shares

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     19,538,650 Ordinary Shares and 4,223,110 American Depositary Shares

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     19,538,650 Ordinary Shares and 4,223,110 American Depositary Shares

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     N/A

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     7.4%

    12  

     TYPE OF REPORTING PERSON*

     

     IA

    PAGE 2 OF 5 PAGES


    Item 1(a) 

    Name of Issuer:

    FRESENIUS MEDICAL CARE AG

     

    Item 1(b) 

    Address of Issuer’s Principal Executive Offices:

    Else-Kröner Strasse 1

    61346 Bad Homburg

    Germany

     

    Item 2(a) 

    Name of Person Filing:

    Dodge & Cox

     

    Item 2(b) 

    Address of the Principal Office or, if none, Residence:

    555 California Street, 40th Floor

    San Francisco, CA 94104

     

    Item 2(c) 

    Citizenship:

    California - U.S.A.

     

    Item 2(d) 

    Title of Class of Securities:

    Ordinary Shares and American Depositary Shares

     

    Item 2(e) 

    CUSIP Number:

    358029106

     

    Item 3 

    If the Statement is being filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

    (e) ☒ Investment Advisor registered under section 203 of the Investment Advisors Act of 1940

     

    Item 4 

    Ownership:

     

      (a)

    Amount Beneficially Owned:

    19,538,650 Ordinary Shares and 4,223,110 American Depositary Shares

     

      (b)

    Percent of Class:

    7.4%

     

    PAGE 3 OF 5 PAGES


      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or direct the vote:

    18,562,650 Ordinary Shares and 4,223,110 American Depositary Shares

     

      (ii)

    shared power to vote or direct the vote:

    0

     

      (iii)

    sole power to dispose or to direct the disposition of:

    19,538,650 Ordinary Shares and 4,223,110 American Depositary Shares

     

      (iv)

    shared power to dispose or to direct the disposition of:

    0

     

    Item 5 

    Ownership of Five Percent or Less of a Class:

    Not applicable.

     

    Item 6 

    Ownership of More than Five Percent on Behalf of Another Person:

    The clients of Dodge & Cox, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or power to direct the receipt of dividends from, and the proceeds from the sale of, FRESENIUS MEDICAL CARE AG.

     

    Item 7 

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

    Not applicable.

     

    Item 8 

    Identification and Classification of Members of the Group:

    Not applicable.

     

    Item 9 

    Notice of Dissolution of a Group:

    Not applicable.

     

    Item 10 

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

     

    PAGE 4 OF 5 PAGES


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 13, 2024

     

    DODGE & COX

    By:

     

    /S/ Katherine M. Primas

    Name:  

    Katherine M. Primas

    Title:

     

    Chief Compliance Officer

     

    PAGE 5 OF 5 PAGES

    Get the next $FMS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FMS

    DatePrice TargetRatingAnalyst
    12/2/2024Underperform → Neutral
    BofA Securities
    11/6/2024$25.60Buy
    Berenberg
    1/8/2024Equal-Weight → Underweight
    Morgan Stanley
    11/24/2023Reduce → Hold
    HSBC Securities
    11/17/2023Hold → Buy
    Societe Generale
    8/14/2023Buy → Neutral
    UBS
    8/1/2023Neutral
    Citigroup
    7/12/2023Buy
    Goldman
    More analyst ratings

    $FMS
    SEC Filings

    See more
    • SEC Form 6-K filed by Fresenius Medical Care AG

      6-K - Fresenius Medical Care AG (0001333141) (Filer)

      5/6/25 4:12:11 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 6-K filed by Fresenius Medical Care AG

      6-K - Fresenius Medical Care AG (0001333141) (Filer)

      5/6/25 6:01:20 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form 6-K filed by Fresenius Medical Care AG

      6-K - Fresenius Medical Care AG (0001333141) (Filer)

      4/10/25 6:01:34 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Fresenius Medical Care AG

      SC 13G - Fresenius Medical Care AG (0001333141) (Subject)

      11/14/24 4:08:53 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13G/A filed by Fresenius Medical Care AG (Amendment)

      SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)

      2/13/24 1:36:58 PM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • SEC Form SC 13D/A filed by Fresenius Medical Care AG (Amendment)

      SC 13D/A - Fresenius Medical Care AG (0001333141) (Subject)

      12/7/23 11:45:52 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Leadership Updates

    Live Leadership Updates

    See more
    • Fresenius Medical Care appoints Jörg Häring as new Management Board member responsible for Legal, Compliance and Human Resources

      Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board roleJörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectorsBAD HOMBURG, Germany, March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announced today the appointment of Jörg Häring (54) as its new Global Head of Legal, Compliance and Human Resources. Häring, who will join the company as a member of the Management Board, will start on June 1, 2024, and also assume the role of Labor Director.

      3/13/24 10:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

      BAD HOMBURG, Germany, Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located in Germany.   Fresenius Medical Care succ

      2/5/24 8:57:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation

      Extraordinary General Meeting approves conversion of Fresenius Medical Care's legal formSeveral advantages including faster and more agile decision-makingMichael Sen elected as Chair of new Supervisory BoardConversion expected to be completed by the end of 2023WALTHAM, Mass., July 14, 2023 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting (EGM) today. The Company's shareholders approved all agenda items with large majority, including the conversion of Fresenius Medical Care from the legal form of a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a

      7/14/23 11:34:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Fresenius Medical upgraded by BofA Securities

      BofA Securities upgraded Fresenius Medical from Underperform to Neutral

      12/2/24 8:51:34 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Berenberg initiated coverage on Fresenius Medical with a new price target

      Berenberg initiated coverage of Fresenius Medical with a rating of Buy and set a new price target of $25.60

      11/6/24 6:26:23 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical downgraded by Morgan Stanley

      Morgan Stanley downgraded Fresenius Medical from Equal-Weight to Underweight

      1/8/24 7:47:44 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Fresenius Medical Care starts 2025 with strong organic revenue and income growth

      Strong organic revenue growth1 of 5% driven by Care Enablement and Care DeliveryStable U.S. same market treatment development despite impact from a severe flu seasonFME25 savings of EUR 68 million contributed to earningsOperating income2 grew 11% at constant currency resulting in margin expansionReported operating income grew by 35% and reported net income3 by 113%Net leverage ratio further improved to 2.8x and FY 2025 outlook confirmedBAD HOMBURG, Germany, May 6, 2025 /PRNewswire/ -- "The results of the first quarter of 2025 once again demonstrate our continuous operational and financial progress as we are executing the third and last year of our current strategic plan," said Helen Giza, Ch

      5/6/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum

      In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholdersFresenius Medical Care delivered 18% operating income growth on an outlook base in 2024Ongoing progress has been achieved in key areas of sustainability: notably in patient care and environmental footprintBAD HOMBURG, Germany, March 13, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, released its 2024 Annual Report including its Sustainability Statement. By "Building the Momentum", the Annual Report highlights financial, social, and ecol

      3/13/25 8:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025

      Organic revenue growth1 of 4% driven by Care Enablement and Care DeliveryUnderlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full yearAccumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to EUR 750 millionWith 18% operating income2 growth top end of the 2024 outlook range reachedReported operating income grew by 2%, reported net income3 by +8%Net financial leverage ratio reduced from 3.2x to 2.9x and dividend is planned to be raised by 21%High teens to high twenties percent earnings growth in 2025, translating into an 11 to 12% marginBAD HOMBURG, Germany, Feb. 25, 2025 /PRNewswire/ -- "Fresenius Medical

      2/25/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care

    $FMS
    Financials

    Live finance-specific insights

    See more
    • Fresenius Medical Care starts 2025 with strong organic revenue and income growth

      Strong organic revenue growth1 of 5% driven by Care Enablement and Care DeliveryStable U.S. same market treatment development despite impact from a severe flu seasonFME25 savings of EUR 68 million contributed to earningsOperating income2 grew 11% at constant currency resulting in margin expansionReported operating income grew by 35% and reported net income3 by 113%Net leverage ratio further improved to 2.8x and FY 2025 outlook confirmedBAD HOMBURG, Germany, May 6, 2025 /PRNewswire/ -- "The results of the first quarter of 2025 once again demonstrate our continuous operational and financial progress as we are executing the third and last year of our current strategic plan," said Helen Giza, Ch

      5/6/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care publishes its joint Annual Report and Sustainability Statement for 2024: Building the Momentum

      In 2024, the operating model to deliver the highest quality of patient care was further optimized by enhancing financial returns, and creating value for shareholdersFresenius Medical Care delivered 18% operating income growth on an outlook base in 2024Ongoing progress has been achieved in key areas of sustainability: notably in patient care and environmental footprintBAD HOMBURG, Germany, March 13, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, released its 2024 Annual Report including its Sustainability Statement. By "Building the Momentum", the Annual Report highlights financial, social, and ecol

      3/13/25 8:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care
    • Fresenius Medical Care delivers 18% earnings growth in 2024 and continues the acceleration momentum into 2025

      Organic revenue growth1 of 4% driven by Care Enablement and Care DeliveryUnderlying U.S. same market treatment growth further accelerated in Q4 and turned positive for the full yearAccumulated savings of the FME25 program already reached EUR 567 million and 2025 target raised to EUR 750 millionWith 18% operating income2 growth top end of the 2024 outlook range reachedReported operating income grew by 2%, reported net income3 by +8%Net financial leverage ratio reduced from 3.2x to 2.9x and dividend is planned to be raised by 21%High teens to high twenties percent earnings growth in 2025, translating into an 11 to 12% marginBAD HOMBURG, Germany, Feb. 25, 2025 /PRNewswire/ -- "Fresenius Medical

      2/25/25 7:00:00 AM ET
      $FMS
      Misc Health and Biotechnology Services
      Health Care